Akums Drugs and Pharmaceuticals announced a consolidated net profit of 1,145.65 million for the quarter ended September 30, 2026, on revenues of 13,423.87 million. The company also completed a 560 million acquisition of Oriflamme India’s manufacturing assets to bolster its skincare and cosmetics business. Additionally, the company disclosed a 1,560.18 million income tax demand, which is currently under legal appeal.
Akums Drugs Posts Q2 Profit of 1,145 Million and Announces Expansion
Akums Drugs and Pharmaceuticals reported a consolidated net profit of 1,145.65 million for the second quarter of FY2027. Consolidated revenue from operations for the same period stood at 13,423.87 million.
Reader Takeaway: Strong operational growth via strategic acquisitions, tempered by a significant ongoing tax litigation matter to monitor.
What just happened
Akums Drugs released its financial results for the quarter ending September 30, 2026, highlighting steady performance with a six-month profit totaling 2,155.43 million. Simultaneously, the company's subsidiary, Pure and Cure Healthcare, finalized the acquisition of Oriflamme India's manufacturing business for 560 million. This deal secures manufacturing facilities in Roorkee and Noida to support growth in wellness and color cosmetics.
Why this matters
The acquisition allows Akums to vertically integrate its manufacturing capabilities in high-growth segments like skincare and cosmetics. While the financial results remain stable, the company has officially confirmed it has fully utilized its IPO proceeds, signaling a transition toward organic and inorganic growth using operational cash flows.
Risks to watch
Investors must monitor a tax demand of 1,560.18 million raised by income-tax authorities for the period between April 2018 and March 2025. Akums has contested this claim, filed an appeal, and deposited 109.74 million under protest. Management currently believes no financial adjustments are necessary, but the scale of the claim remains a material factor.
Governance Update
The Board of Directors has designated Mr. Sanjay Kumar, the company's President of Operations, as Senior Management Personnel, effective November 02, 2026, to streamline executive oversight.
What to track next
Watch for integration updates regarding the newly acquired Oriflamme manufacturing units and any further legal developments regarding the tax appeal status in upcoming quarterly disclosures.